BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The data presented at ELCC 2026 demonstrate the potential of BioNTech's late-stage lung cancer portfolio, with updates on Pumitamig and Gotistobart as well as first clinical data for HER3-targeted ADC candidate BNT326/YL202, driving forward differentiated treatment approaches for various lung cancer stages

  60% confidence

• Gotistobart showed a clinically relevant overall survival benefit with a 54% reduction in mortality risk compared to current standard of care in second-line and later treatment of squamous lung cancer

  60% confidence

• Pumitamig data support the currently ongoing registrational Phase 3 trial ROSETTA Lung-01 for first-line treatment of extensive-stage small cell lung cancer

  60% confidence

• BioNTech currently has 16 clinical trials running for various lung cancer subtypes and treatment lines, including four registrational Phase 3 trials and five trials with innovative combination approaches

  60% confidence

• BioNTech's goal is to offer patients with lung cancer innovative treatment options that aim to enable significant long-term benefit across all disease stages

  60% confidence

Data points we hold from this source